FindTrial
Sign In

To investigate the prognosis of cervical cancer patients with concurrent chemoradiotherapy based on multimodal data fusion

To investigate the prognosis of cervical cancer patients with concurrent chemoradiotherapy based on multimodal data fusion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098856
Enrollment
Unknown
Registered
2025-03-14
Start date
2024-03-07
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Observation group:None

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. histopathologically confirmed cervical squamous cell carcinoma; 2. the presence of measurable lesions in the cervical tumor assessed by MRI; 3.The treatment was concurrent chemoradiotherapy; 4. pretreatment MRI scans within 3 weeks before treatment; 5. squamous cell carcinoma antigen (SCC) test results >=1.5µg/L within 3 weeks before treatment; 6. Complete follow-up information at 1, 3, and 5 years after treatment.

Exclusion criteria

Exclusion criteria: 1. concurrent malignancy or a history of cancer; 2. neoadjuvant therapy; 3. missing MRI data or insufficient image quality; 4. missing or incomplete clinical follow-up data.

Design outcomes

Primary

MeasureTime frame
OS,Overall Survival;Disease Free Survival;—

Countries

China

Contacts

Public ContactYue Feng

Zhejiang Cancer Hospital

fengyue@zjcc.org.cn+86 152 2406 5122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026